Compare interventions

Use the same six evidence dimensions for both. This prevents a strong animal result for one product being compared with a human clinical result for another.

First intervention

versus

Second intervention

Amino acid derivative

Taurine

Promising, incomplete

Compelling animal ageing biology; human longevity claims remain untested.

Human clinical outcomes Preliminary

Human biomarkers Limited

Animal lifespan Strong

Mechanistic plausibility Moderate

Safety certainty Limited

Direct longevity relevance Preliminary

Verdict: Taurine is scientifically interesting because circulating levels tend to fall with age and supplementation extended lifespan in mice in a prominent 2023 study. The human part of that paper was associative, not proof that taurine slows human ageing. Small human studies examine exercise, metabolic or disease-specific outcomes, but no trial has shown longer life or broad reversal of ageing in people.

Open full dossier

NAD+ precursor

NMN

Early human evidence

Raises NAD-related biomarkers; broad healthspan benefits have not followed reliably.

Human clinical outcomes Preliminary

Human biomarkers Moderate

Animal lifespan Limited

Mechanistic plausibility Moderate

Safety certainty Limited

Direct longevity relevance Preliminary

Verdict: Nicotinamide mononucleotide can raise NAD-related measures in humans, which confirms biological activity. Trials have reported selected metabolic or functional effects, but results are mixed, studies are generally short, and no human evidence shows slower ageing or longer life.

Open full dossier